-

Zoetis Announces Time Change for Second Quarter 2024 Financial Results Webcast and Conference Call

PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) will now host its second-quarter 2024 financial results webcast and conference call at 8:00 a.m. (ET) on Tuesday, August 6, 2024, to minimize conflicts with other industry earnings announcements.

Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/events-presentations. There is no change to the webcasting information. A replay of the webcast will be made available on August 6, 2024.

About Zoetis

As the world’s leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock farmers and ranchers. The company’s leading portfolio and pipeline of medicines, vaccines, diagnostics and technologies make a difference in over 100 countries. A Fortune 500 company, Zoetis generated revenue of $8.5 billion in 2023 with approximately 14,100 employees. For more information, visit www.zoetis.com.

ZTS-COR
ZTS-IR

Contacts

Media Contacts:
Jennifer Albano
1-862-399-0810 (o)
Jennifer.albano@zoetis.com

Laura Panza
1-973-975-5176 (o)
laura.panza@zoetis.com

Investor Contacts:
Steve Frank
1-973-822-7141 (o)
steve.frank@zoetis.com

Nick Soonthornchai
1-973-443-2792 (o)
nick.soonthornchai@zoetis.com

Industry:

Zoetis Inc.

NYSE:ZTS
Release Versions
English
$Cashtags
$ZTS
Hashtags
#animalhealth
#earnings
#fortune500

Contacts

Media Contacts:
Jennifer Albano
1-862-399-0810 (o)
Jennifer.albano@zoetis.com

Laura Panza
1-973-975-5176 (o)
laura.panza@zoetis.com

Investor Contacts:
Steve Frank
1-973-822-7141 (o)
steve.frank@zoetis.com

Nick Soonthornchai
1-973-443-2792 (o)
nick.soonthornchai@zoetis.com

Social Media Profiles
Zoetis on Facebook
Zoetis on LinkedIn
Zoetis on Twitter
More News From Zoetis Inc.

Zoetis Launches Lenivia® (izenivetmab injection) in Canada and the European Union

PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE: ZTS) today announced that it has recently launched Lenivia® (izenivetmab injection) in Canada and the European Union (EU) member states – a new long-acting monoclonal antibody (mAb) therapy designed to deliver up to three months of osteoarthritis (OA) pain management with a single subcutaneous injection. Backed by a decade of science and research, Lenivia demonstrated a sustained reduction in pain in a pivotal nine-month European field study...

Zoetis Announces Agreement to Acquire VitalRADS, Accelerating Diagnostic Capabilities

PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. today announced its agreement to acquire VitalRADS, a veterinary teleradiology services platform. Building on the partnership with VitalRADS that Zoetis announced in August 2025, this acquisition adds around-the-clock access to board-certified veterinary specialists through a cloud-based teleradiology platform. Integrating VitalRADS’ capabilities into Zoetis’ Global Diagnostics portfolio enhances Zoetis’ reference laboratory services, delivering AI...

Zoetis Receives European Commission Marketing Authorization for Poulvac® Procerta® HVT-ND

PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE: ZTS) today announced that the European Commission (EC) has granted marketing authorization for Poulvac® Procerta® HVT-ND, a recombinant vector vaccine for the protection of chickens against Newcastle disease (ND) and Marek’s disease viruses. The vaccine can be administered either in ovo or by subcutaneous injection at hatch, providing protection against both diseases with a single dose. Newcastle disease is a notifiable disease under EU anim...
Back to Newsroom